Randall Lanier Selected Research

brincidofovir

1/2020	Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT.
10/2017	The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak.
5/2012	Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.
4/2012	Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
1/2011	Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
12/2010	Development of CMX001 for the Treatment of Poxvirus Infections.
3/2009	Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
1/2008	Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Randall Lanier Research Topics

Disease

7	Infections 01/2021 - 01/2008
5	Smallpox (Variola) 10/2017 - 01/2008
3	Infectious Ectromelia 04/2012 - 01/2008
2	Viremia 01/2020 - 05/2012
2	Ectromelia (Phocomelia) 04/2012 - 03/2009
2	Poxviridae Infections 01/2011 - 12/2010
2	Mpox (monkeypox) 01/2011 - 01/2008
1	Cytokine Release Syndrome 01/2021
1	COVID-19 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Hemorrhage 01/2021
1	Respiratory Insufficiency (Respiratory Failure) 01/2021
1	Adenoviridae Infections (Adenovirus Infections) 05/2012
1	Exanthema (Rash) 04/2012
1	Cytomegalovirus Infections (Inclusion Disease) 12/2010
1	Virus Diseases (Viral Diseases) 12/2010
1	Weight Loss (Weight Reduction) 01/2008
1	Disease Progression 01/2008

Drug/Important Bio-Agent (IBA)

8	brincidofovirIBA 01/2020 - 01/2008
5	Antiviral Agents (Antivirals)IBA 10/2017 - 01/2008
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2008
2	Biological Warfare AgentsIBA 10/2017 - 04/2012
2	tecovirimatIBA 10/2017 - 04/2012
2	Viral DNAIBA 04/2012 - 01/2008
2	Cidofovir (Vistide)FDA Link 01/2011 - 01/2008
1	fibrin fragment D (D-dimer)IBA 01/2021
1	GlycosaminoglycansIBA 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	SodiumIBA 01/2021
1	HMGB1 Protein (HMG1)IBA 01/2021
1	VaccinesIBA 10/2017
1	Indicators and Reagents (Reagents)IBA 04/2012
1	NucleotidesIBA 01/2011
1	AerosolsIBA 01/2011
1	TabletsIBA 12/2010
1	DNA (Deoxyribonucleic Acid)IBA 12/2010
1	AntigensIBA 03/2009
1	CytokinesIBA 03/2009
1	EstersIBA 01/2008
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2008
1	Biological ProductsIBA 01/2008
1	Alanine Transaminase (SGPT)IBA 01/2008
1	Interferon-gamma (Interferon, gamma)IBA 01/2008

Therapy/Procedure

5	Therapeutics 05/2012 - 01/2008
1	Critical Care (Surgical Intensive Care) 01/2021
1	Length of Stay 01/2021
1	Salvage Therapy 05/2012
1	Oral Administration 12/2010